Signifor (pasireotide) 0.9 mg/mL solution for injection, 1 mL ampoules *60 Acromegaly Treatment Drug delivery from Europe and beyond, within 4-5 days, storage conditions are met, payment upon receipt. Order by calling +380996042415, Viber, WhatsApp.

Treatment of adult patients with acromegaly for whom surgical treatment is not optimal or has been limited and for whom adequate monitoring of another somatostatin analogue is not ensured.

Treatment of adult patients with Cushing's disease, for whom surgical treatment is not optimal or was not remote.

Dose 60 mg stagnant only for treatment acromegaly.

Dozuvannya.

Acromegaly.

For the treatment of acromegaly, the recommended dose is 40 mg of pasireotide skin 4 days.

The dose may be increased to a maximum of 60 mg for patients in whom growth hormone (GH) and/or insulin-like growth factor 1 (IGF-1) levels are not adequately controlled after 3 months of drug treatment in dose 40 mg.

To control suspected side effects A reaction or an over-the-top response to treatment (IGF-1 < lower reference range) may require an immediate dose reduction. The dose can be changed hourly or gradually.

Cushing's disease.

The recommended daily dose for the treatment of Cushing's disease is 10 mg pasireotide for deep internal ulcerative skin injections for 4 days.